New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
16:10 EDTRHHBY, PRTAProthena says first human dosed in Phase 1 study of PRX002
Prothena (PRTA) announced the successful start of a Phase 1 clinical trial of its therapeutic monoclonal antibody candidate, PRX002, for the treatment of Parkinson's disease. Prothena has earned a $15M milestone payment from Roche (RHHBY) related to the initiation of this study. The initial Phase 1 clinical trial of PRX002 is a randomized, double-blind, placebo-controlled, single ascending dose study in healthy subjects. It is designed to assess PRX002 for safety, tolerability, pharmacokinetics and immunogenicity. As previously announced in December 2013, Prothena entered into a worldwide collaboration with Roche to develop and commercialize antibodies that target α-synuclein, including PRX002. Including the current milestone payment, Prothena has now achieved a total of $45M through its worldwide PRX002 collaboration with Roche.
News For PRTA;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 22, 2015
15:14 EDTRHHBYExelixis confirms Phase 3 data on Cotellic with Zelboraf for melanoma
Subscribe for More Information
15:09 EDTRHHBYGenentech reports data on Cotellic with Zelboraf for treatment of melanoma
Genentech, a member of the Roche Group, announced data from the pivotal coBRIM study, showing that Cotellic, or cobimetinib, in combination with Zelboraf, or vemurafenib, helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live "significantly longer" than with Zelboraf alone, according to the company. Cotellic plus Zelboraf reduced the risk of death by 30% compared to Zelboraf alone and helped people live a median of nearly two years, with 74.5% of BRAF V600 patients alive at one year and 48.3% alive at two years. Ongoing study monitoring did not identify any new safety signals. The company noted that an approval decision on Cotellic from the European Commission is expected before year end.
November 19, 2015
07:29 EDTPRTAProthena price target raised to $95 from $75 at RBC Capital
RBC Capital says that the data on Prothena's orphan amyloidosis drug continues to look strong, while regulators in Europe and the U.S. are becoming more favorably disposed to the treatment. RBC is upbeat on the company's new Parkinson's drug and expects positive data for the drug to be reported in 1H16. It views the stock as undervalued and keeps an Outperform rating on the shares.
November 18, 2015
08:28 EDTRHHBYLeerink to hold a bus tour
Subscribe for More Information
08:11 EDTRHHBYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
November 17, 2015
07:34 EDTRHHBYOphthotech to hold a conference call
Subscribe for More Information
06:08 EDTRHHBYRoche subsidiary to participate in Ophthotech and Novartis agreement
Subscribe for More Information
November 13, 2015
10:18 EDTRHHBYRoche receives FDA approval for cobas EGFR mutation test
Subscribe for More Information
09:34 EDTRHHBYFDA approves Roche's cobas EGFR Mutation Test
Subscribe for More Information
November 12, 2015
11:50 EDTRHHBYRoche to restructure manufacturing network for small molecules
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use